Cancer
Malignant Bladder Neoplasm
CI-CAN-00005866Explore in graph →
Top-level346 active trials10 approved drugs25 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00005866Explore in graph →
Clinical trials
1,510 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (179)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06290687 | Partial Cystectomy & Extended Pelvic Lymph Node Dissection With SOC Perioperative Systemic Therapy | withdrawn | Phase 2 | 0 | Case Comprehensive Cancer CenterOTHER | 0 | Sep 24, 2026 | clinicaltrials |
| NCT07414992 | A Study of Radiation Therapy and Cemiplimab With or Without Fianlimab In People With Bladder Cancer | withdrawn | Phase 2 | 0 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT02143804 | Safety and Efficacy of CG0070 Oncolytic Virus Regimen in Patients With High Grade Non-Muscle Invasive Bladder Cancer(exBOND) | withdrawn | Phase 2 | 0 | CG Oncology, Inc.INDUSTRY | 1 | Apr 2, 2026 | clinicaltrials |
| NCT05564416 | Testing Anti-Cancer Drugs Erdafitinib With or Without Atezolizumab in Patients With Localized Bladder Cancer Not Able to Receive Cisplatin Chemotherapy, NERA Trial | withdrawn | Phase 2 | 0 | National Cancer Institute (NCI)NIH | 0 | Oct 21, 2025 | clinicaltrials |
| NCT05120622 | Trial of Local Cystoscopic Injection of Tremelimumab Plus Systemic Durvalumab for High Risk Non-Muscle Invasive Bladder Cancer(Rideau) | withdrawn | Phase 1 / Phase 2 | 0 | University of British ColumbiaOTHER | 1 | Oct 31, 2023 | clinicaltrials |
| NCT04464967 | Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers | withdrawn | Phase 1 / Phase 2 | 0 | NKGen Biotech, Inc.INDUSTRY | 0 | May 12, 2021 | clinicaltrials |
| NCT03517995 | Randomized, Phase II Clinical Trial of Sulforaphane in Bladder Cancer Chemoprevention | withdrawn | Phase 2 | 0 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | May 28, 2020 | clinicaltrials |
| NCT03935347 | Adoptive Cell Therapy With (LN-145) in Combination With Pembrolizumab in Treating Patients With Unresectable or Metastatic Transitional Cell Cancer Who Have Failed Cisplatin-Based Chemotherapy | withdrawn | Phase 2 | 0 | Roswell Park Cancer InstituteOTHER | 1 | Jan 2, 2020 | clinicaltrials |
| NCT04040725 | Rogaratinib for BCG Refractory High Risk Non-Muscle Invasive Bladder Cancer With FGFR1/2 Overexpression | withdrawn | Phase 2 | 0 | Dana-Farber Cancer InstituteOTHER | 0 | Dec 17, 2019 | clinicaltrials |
| NCT03419130 | Radiation Therapy and Pembrolizumab in Treating Patients With Localized Urothelial Bladder Cancer | withdrawn | Phase 2 | 0 | University of California, San FranciscoOTHER | 1 | Dec 7, 2018 | clinicaltrials |
| NCT02845050 | Phase Ib/II Study Assessing the Neo-adjuvant Combination Therapy of Vinflunine With Cisplatin Followed by Radical Cystectomy in Patients With Muscle-invasive Bladder Cancer (JaNEO)(JaNEO) | withdrawn | Phase 1 / Phase 2 | 0 | Ligartis GmbHINDUSTRY | 1 | Feb 13, 2018 | clinicaltrials |
| NCT03150836 | Radiation Therapy and Durvalumab, With or Without Tremelimumab, in Patients With Bladder Cancer | withdrawn | Phase 2 | 0 | Terence Friedlander, MDOTHER | 1 | Oct 19, 2017 | clinicaltrials |
| NCT02718742 | Paclitaxel Albumin-Stabilized Nanoparticle Formulation After Cisplatin-Based Chemotherapy and Surgery in Treating Patients With High-Risk Bladder Cancer | withdrawn | Phase 2 | 0 | Mayo ClinicOTHER | 1 | Apr 18, 2016 | clinicaltrials |
| NCT01639521 | Gemcitabine Hydrochloride and Cisplatin or High-Dose Methotrexate, Vinblastine, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Urothelial Cancer | withdrawn | Phase 2 | 0 | University of Southern CaliforniaOTHER | 0 | Jan 29, 2014 | clinicaltrials |
| NCT01700010 | Trial of Lapatinib and Weekly Paclitaxel for Advanced Urothelial Cancer | withdrawn | Phase 2 | 0 | University of Michigan Rogel Cancer CenterOTHER | 1 | Jan 17, 2013 | clinicaltrials |
Data updated 4 days agoSource updated Sep 24, 2026source: clinicaltrials